Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Data on synthesis, ADME and pharmacological properties and early safety pharmacology evaluation of a series of novel NURR1/NOT agonist potentially useful for the treatment of Parkinson's disease.
Malanda A, Abécassis PY, Barnéoud P, Brunel P, Taupin V, Vigé X, Lesuisse D. Malanda A, et al. Among authors: lesuisse d. Data Brief. 2019 May 27;27:104057. doi: 10.1016/j.dib.2019.104057. eCollection 2019 Dec. Data Brief. 2019. PMID: 31687426 Free PMC article.
Development of a novel NURR1/NOT agonist from hit to lead and candidate for the potential treatment of Parkinson's disease.
Lesuisse D, Malanda A, Peyronel JF, Evanno Y, Lardenois P, De-Peretti D, Abécassis PY, Barnéoud P, Brunel P, Burgevin MC, Cegarra C, Auger F, Dommergue A, Lafon C, Even L, Tsi J, Luc TPH, Almario A, Olivier A, Castel MN, Taupin V, Rooney T, Vigé X. Lesuisse D, et al. Bioorg Med Chem Lett. 2019 Apr 1;29(7):929-932. doi: 10.1016/j.bmcl.2019.01.024. Epub 2019 Jan 30. Bioorg Med Chem Lett. 2019. PMID: 30773432
Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T. Lesuisse D, et al. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1985-9. doi: 10.1016/j.bmcl.2010.01.114. Epub 2010 Jan 25. Bioorg Med Chem Lett. 2010. PMID: 20167481
Exploring ITM2A as a new potential target for brain delivery.
Cegarra C, Chaves C, Déon C, Do TM, Dumas B, Frenzel A, Kuhn P, Roudieres V, Guillemot JC, Lesuisse D. Cegarra C, et al. Among authors: lesuisse d. Fluids Barriers CNS. 2022 Mar 21;19(1):25. doi: 10.1186/s12987-022-00321-3. Fluids Barriers CNS. 2022. PMID: 35313913 Free PMC article.
Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors.
Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G, Hittinger A, Ruf S, Strobel H, Nair A, Ritter K, Malleron JL, Dagallier A, El-Ahmad Y, Guilloteau JP, Guizani H, Bouchard H, Venot C. Lesuisse D, et al. Bioorg Med Chem Lett. 2011 Apr 15;21(8):2224-8. doi: 10.1016/j.bmcl.2011.03.003. Epub 2011 Mar 4. Bioorg Med Chem Lett. 2011. PMID: 21441024
Design of potent IGF1-R inhibitors related to bis-azaindoles.
Nemecek C, Metz WA, Wentzler S, Ding FX, Venot C, Souaille C, Dagallier A, Maignan S, Guilloteau JP, Bernard F, Henry A, Grapinet S, Lesuisse D. Nemecek C, et al. Among authors: lesuisse d. Chem Biol Drug Des. 2010 Aug;76(2):100-6. doi: 10.1111/j.1747-0285.2010.00991.x. Epub 2010 Jun 9. Chem Biol Drug Des. 2010. PMID: 20545947
34 results